PacBio Hints at Low-Cost Future Instruments; Aims to Capture 10 Percent of NGS Market | GenomeWeb

By Julia Karow

Pacific Biosciences aims to capture about 10 percent of the next-gen sequencing market over the next several years, according to a company executive. The official also hinted that the firm, which is on track to ship its first commercial sequencer to customers during the first half of this year, might launch lower-cost instruments in the future.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.